The Filing Desk

CareDx vs Veracyte

CareDx CDNA · Veracyte VCYT · Health Care Services

Veracyte reported revenue of $517 million in fiscal 2025, 1.4 times CareDx's $380 million in fiscal 2025. CareDx's revenue grew 13.8% in its latest year, and Veracyte's grew 16.0%. CareDx had an operating margin of -8.1%, against 11.2% at Veracyte.

Side by side

CareDxVeracyte
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$380M$517M
Revenue growth13.8%16.0%
Revenue growth a year, last 5 years14.6%34.5%
Gross margin—70.1%
Operating margin−8.1%11.2%
Net margin−5.6%12.8%
Free cash flow—$127M
Free cash flow margin—24.5%
Return on capital−20.0%6.1%
Net debt to EBITDA—−4.6x
Dividends and buybacks$88M$0M
Change in diluted share count−5.9%3.1%
Last close$77.88$24.33
P/E at the last close32.6×15.8×
Insider trades, last 12 monthssold $13.6 millionsold $19.2 million
Piotroski F-score4 of 86 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
CareDxVeracyte
Operating margin
Percent of revenue
CareDxVeracyte
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
CareDxVeracyte

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the CareDx and Veracyte pages.